Langerhans’-cell histiocytosis (LCH) is a rare disorder characterized by tissue infiltrates of CD1a+ Langerhans’ cells, eosinophils, neutrophils, macrophages, and lymphocytes. Systemic treatments for refractory LCH are unsatisfactory and usually toxic. We report the use of imatinib mesylate to control parenchymal brain involvement in a patient with multisystem LCH.

Imatinib mesylate for cerebral Langerhans'-cell histiocytosis / Montella, L; Insabato, Luigi; Palmieri, Giovannella. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - STAMPA. - 351:10(2004), pp. 1034-1035.

Imatinib mesylate for cerebral Langerhans'-cell histiocytosis.

INSABATO, LUIGI;PALMIERI, GIOVANNELLA
2004

Abstract

Langerhans’-cell histiocytosis (LCH) is a rare disorder characterized by tissue infiltrates of CD1a+ Langerhans’ cells, eosinophils, neutrophils, macrophages, and lymphocytes. Systemic treatments for refractory LCH are unsatisfactory and usually toxic. We report the use of imatinib mesylate to control parenchymal brain involvement in a patient with multisystem LCH.
2004
Imatinib mesylate for cerebral Langerhans'-cell histiocytosis / Montella, L; Insabato, Luigi; Palmieri, Giovannella. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - STAMPA. - 351:10(2004), pp. 1034-1035.
File in questo prodotto:
File Dimensione Formato  
Imatinib mesylate 2004.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 166.58 kB
Formato Adobe PDF
166.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/337599
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 50
  • ???jsp.display-item.citation.isi??? ND
social impact